25 XP 0   0   10  
0coffee
Main menu
3rd party ad coffee SUPPORTERis ad-free.

NEU (Neuren Pharmaceuticals Ltd) Stock Analysis
Buy, Hold or Sell?

Let's analyze Neuren Pharmaceuticals Ltd together

I guess you are interested in Neuren Pharmaceuticals Ltd. Buy, hold or sell? I don't know! However, I do recommend doing research before doing anything. I will help you with that.

  • 📊 Fundamental Analysis (FA) – Neuren Pharmaceuticals Ltd’s Financial Insights
  • 📈 Technical Analysis (TA) – Neuren Pharmaceuticals Ltd’s Price Targets

I'm going to help you getting a better view of Neuren Pharmaceuticals Ltd. At the end you don't have to ask anyone for trading advice. You can make your own decision, with more confidence, the odds in your favor, backed by data.

Get notifications about Neuren Pharmaceuticals Ltd

I send you an email if I find something interesting about Neuren Pharmaceuticals Ltd.

1. Quick Overview

1.1. Quick analysis of Neuren Pharmaceuticals Ltd (30 sec.)










1.2. What can you expect buying and holding a share of Neuren Pharmaceuticals Ltd? (30 sec.)

How much money do you get?

How much money do you get?
A$0.00
When do you have the money?
1 year
How often do you get paid?
0.0%

What is your share worth?

Current worth
A$2.78
Expected worth in 1 year
A$7.64
How sure are you?
70.0%

+ What do you gain per year?

Total Gains per Share
A$4.85
Return On Investment
33.3%

For what price can you sell your share?

Current Price per Share
A$14.57
Expected price per share
A$14.50 - A$18.16
How sure are you?
50%
3rd party ad coffee SUPPORTERis ad-free.

2. Detailed Analysis

2.1. Valuation of Neuren Pharmaceuticals Ltd (5 min.)




Live pricePrice per Share (EOD)
A$14.57
Intrinsic Value Per Share
A$0.55 - A$3.92
Total Value Per Share
A$3.33 - A$6.70

2.2. Growth of Neuren Pharmaceuticals Ltd (5 min.)




Is Neuren Pharmaceuticals Ltd growing?

Current yearPrevious yearGrowGrow %
How rich?$239.5m$135m$104.4m43.6%

How much money is Neuren Pharmaceuticals Ltd making?

Current yearPrevious yearGrowGrow %
Making money$93.4m$103.3m-$9.8m-10.6%
Net Profit Margin66.6%67.7%--

How much money comes from the company's main activities?

2.3. Financial Health of Neuren Pharmaceuticals Ltd (5 min.)




2.4. Comparing to competitors in the Biotechnology industry (5 min.)




  Industry Rankings (Biotechnology)  


Richest
#221 / 872

Most Revenue
#71 / 872

Most Profit
#28 / 872
3rd party ad coffee SUPPORTERis ad-free.

3. Summary and Key Metrics

3.1. What can you expect buying and holding a share of Neuren Pharmaceuticals Ltd?

Welcome investor! Neuren Pharmaceuticals Ltd's management wants to use your money to grow the business. In return you get a share of Neuren Pharmaceuticals Ltd.

First you should know what it really means to hold a share of Neuren Pharmaceuticals Ltd. And how you can make/lose money.

Speculation

The Price per Share of Neuren Pharmaceuticals Ltd is A$14.57. The market price reflects what other people think it is worth; not what it's really worth. Your job is to find out if the market price is fair, overpriced, or underpriced. I will help you with that.

If you buy blind, there is a 50% chance of making or losing money by selling the stock in the future. However, we can look at a few things to determine the odds in our favor:

  • The fundamentals: the financial health trends of Neuren Pharmaceuticals Ltd.
  • The technials: based on market psychology, we can make a calculated estimate of what the price will do in the future. We can do this through technical analysis. We can calculate the probabilities and the expected value (millionaire math). That's called speculation.
  • The book value: what is the market price compared to it's book value.

Investing

If you really want to invest in Neuren Pharmaceuticals Ltd, you will have to let go of the thought of selling in the future. If you have to sell the share for less than you bought it, it can still be a good investment. Focus on what it means to hold the stock forever:

  • You own a part of the company. The equity of this part can grow or shrink. The current Book Value per Share is A$2.78. Based on the TTM, the Book Value Change Per Share is A$1.21 per quarter. Based on the YOY, the Book Value Change Per Share is A$1.25 per quarter.
  • You may receive quarterly/yearly dividend in the form of additional shares.
  • You may receive quarterly/yearly dividend in the form of cash. Based on the TTM the Dividend per Share is A$0.00 per quarter.
Based on historical numbers we can estimate the returns while holding a share of Neuren Pharmaceuticals Ltd.

How much money are you going to get?

 MRQTTMYOY3Y5Y10Y
 A$% of Price per ShareA$% of Price per ShareA$% of Price per ShareA$% of Price per ShareA$% of Price per ShareA$% of Price per Share
Usd Eps0.714.9%0.714.9%0.795.4%0.503.4%0.281.9%0.130.9%
Usd Book Value Change Per Share0.805.5%0.805.5%0.825.6%0.543.7%0.352.4%0.171.2%
Usd Dividend Per Share0.000.0%0.000.0%0.000.0%0.000.0%0.000.0%0.000.0%
Usd Total Gains Per Share0.805.5%0.805.5%0.825.6%0.543.7%0.352.4%0.171.2%
Usd Price Per Share8.23-8.23-16.44-9.97-6.64-3.80-
Price to Earnings Ratio11.51-11.51-20.79-1,867.34-1,104.69-567.29-
Price-to-Total Gains Ratio10.30-10.30-20.03-249.57-159.18-81.76-
Price to Book Ratio4.49-4.49-15.91-15.02-12.77-12.09-
Price-to-Total Gains Ratio10.30-10.30-20.03-249.57-159.18-81.76-

When do you get the money?

Usd Investment
$.00
Usd Price Per Share9.589974
Number of shares104
Gains per QuarterTrailing 12 Months5 Year
Usd Dividend Per Share0.000.00
Usd Book Value Change Per Share0.800.35
Usd Total Gains Per Share0.800.35
Gains per Quarter (104 shares)83.0636.59
Gains per Year (104 shares)332.22146.36
YearsReturn on Investment (TTM)Return on Investment (5Y)
 DividendBook Value gainTotal gainsDividendBook Value gainTotal gains
Broker costs---10---10
103323220146136
206646540293282
309979860439428
40132913180585574
50166116500732720
60199319820878866
7023262314010251012
8026582646011711158
9029902978013171304
10033223310014641450

How sure are you?

Based on the past periods, how sure are you to get value out of your investment.

Linear %
 Trailing 12 Months3Y5 Year10 YearALLTIME
  % % % % %
Earnings Per Share1.00.00.0100.0%3.00.00.0100.0%3.02.00.060.0%5.05.00.050.0%6.017.02.024.0%
Book Value Change Per Share1.00.00.0100.0%3.00.00.0100.0%5.00.00.0100.0%7.03.00.070.0%13.012.00.052.0%
Dividend per Share0.00.01.00.0%0.00.03.00.0%0.00.05.00.0%0.00.010.00.0%0.00.025.00.0%
Total Gains per Share1.00.00.0100.0%3.00.00.0100.0%5.00.00.0100.0%7.03.00.070.0%13.012.00.052.0%
3rd party ad coffee SUPPORTERis ad-free.

3.2. Key Performance Indicators

The key performance indicators of Neuren Pharmaceuticals Ltd compared to the Most Recent Quarter (MRQ).

 End of day+/-Most Recent QuarterTrailing 12 Months+/-Year-Over-Year+/-3Y+/-5 Year+/-10 Year+/-
Book Value Change Per Share--1.2131.2130%1.247-3%0.824+47%0.535+127%0.263+361%
Book Value Per Share--2.7832.7830%1.569+77%1.558+79%1.036+169%0.576+383%
Current Ratio--8.7268.7260%5.780+51%13.426-35%24.654-65%18.236-52%
Debt To Asset Ratio--0.1120.1120%0.172-35%0.108+4%0.075+50%0.105+7%
Debt To Equity Ratio--0.1260.1260%0.208-40%0.125+1%0.085+48%0.130-3%
Dividend Per Share----0%-0%-0%-0%-0%
Enterprise Value--1811185262.5001811185262.5000%3451065120.390-48%2108526297.713-14%1404374668.628+29%799085681.314+127%
Eps--1.0861.0860%1.201-10%0.763+42%0.431+152%0.192+467%
Ev To Ebitda Ratio--10.31610.3160%17.319-40%-214.271+2177%-145.198+1508%-57.276+655%
Ev To Sales Ratio--8.4948.4940%14.880-43%32.147-74%102.950-92%185.124-95%
Free Cash Flow Per Share---0.086-0.0860%1.414-106%0.452-119%0.242-136%0.093-193%
Free Cash Flow To Equity Per Share---0.153-0.1530%1.442-111%0.439-135%0.300-151%0.143-207%
Gross Profit Margin--1.0001.0000%1.000+0%0.982+2%0.989+1%1.010-1%
Intrinsic Value_10Y_max--3.915----------
Intrinsic Value_10Y_min--0.552----------
Intrinsic Value_1Y_max--0.440----------
Intrinsic Value_1Y_min--0.084----------
Intrinsic Value_3Y_max--1.286----------
Intrinsic Value_3Y_min--0.229----------
Intrinsic Value_5Y_max--2.088----------
Intrinsic Value_5Y_min--0.347----------
Market Cap1835674300.000+11%1634745262.5001634745262.5000%3265289120.390-50%1974953631.047-17%1312348068.628+25%747554581.314+119%
Net Profit Margin--0.6660.6660%0.677-2%0.452+47%-2.781+517%-4.215+733%
Operating Margin--0.8230.8230%0.859-4%0.524+57%-2.658+423%-4.393+634%
Operating Ratio--0.1770.1770%0.256-31%0.514-66%3.681-95%6.833-97%
Pb Ratio5.236+14%4.4924.4920%15.912-72%15.015-70%12.767-65%12.094-63%
Pe Ratio13.415+14%11.50911.5090%20.787-45%1867.335-99%1104.690-99%567.289-98%
Price Per Share14.570+14%12.50012.5000%24.970-50%15.140-17%10.095+24%5.773+117%
Price To Free Cash Flow Ratio-168.924-17%-144.924-144.9240%17.661-921%53.000-373%18.276-893%1.842-7967%
Price To Total Gains Ratio12.008+14%10.30210.3020%20.030-49%249.573-96%159.182-94%81.756-87%
Quick Ratio--13.42313.4230%10.626+26%16.214-17%32.233-58%24.399-45%
Return On Assets--0.3470.3470%0.633-45%0.328+6%0.084+311%-0.276+180%
Return On Equity--0.3900.3900%0.765-49%0.387+1%0.116+235%-0.368+194%
Total Gains Per Share--1.2131.2130%1.247-3%0.824+47%0.535+127%0.263+361%
Usd Book Value--239521612.800239521612.8000%135067247.400+77%133987580.000+79%88745500.920+170%49208216.760+387%
Usd Book Value Change Per Share--0.7990.7990%0.821-3%0.542+47%0.352+127%0.173+361%
Usd Book Value Per Share--1.8311.8310%1.033+77%1.026+79%0.682+169%0.379+383%
Usd Dividend Per Share----0%-0%-0%-0%-0%
Usd Enterprise Value--1192122139.7781192122139.7780%2271491062.241-48%1387832009.155-14%924359406.891+29%525958195.441+127%
Usd Eps--0.7150.7150%0.791-10%0.502+42%0.284+152%0.126+467%
Usd Free Cash Flow---7424496.000-7424496.0000%121691307.000-106%38874389.000-119%20946688.440-135%8101520.520-192%
Usd Free Cash Flow Per Share---0.057-0.0570%0.931-106%0.297-119%0.160-136%0.061-193%
Usd Free Cash Flow To Equity Per Share---0.101-0.1010%0.949-111%0.289-135%0.198-151%0.094-207%
Usd Market Cap1208240824.260+11%1075989331.7781075989331.7780%2149213299.041-50%1299914479.955-17%863787498.771+25%492040425.421+119%
Usd Price Per Share9.590+14%8.2288.2280%16.435-50%9.965-17%6.645+24%3.800+117%
Usd Profit--93492702.60093492702.6000%103390714.200-10%65668175.200+42%37164736.440+152%16616588.100+463%
Usd Revenue--140356542.600140356542.6000%152653035.000-8%100862787.400+39%61032911.400+130%31828840.680+341%
Usd Total Gains Per Share--0.7990.7990%0.821-3%0.542+47%0.352+127%0.173+361%
 EOD+5 -3MRQTTM+0 -0YOY+13 -253Y+22 -165Y+26 -1210Y+26 -12

3.3 Fundamental Score

Let's check the fundamental score of Neuren Pharmaceuticals Ltd based on Penke's default stock scanner.

Penke's Stock Scanner

  
  
IndicatorConditionValue
Price to Earnings Ratio (EOD)Between0-1513.415
Price to Book Ratio (EOD)Between0-15.236
Net Profit Margin (MRQ)Greater than00.666
Operating Margin (MRQ)Greater than00.823
Quick Ratio (MRQ)Greater than113.423
Current Ratio (MRQ)Greater than18.726
Debt to Asset Ratio (MRQ)Less than10.112
Debt to Equity Ratio (MRQ)Less than10.126
Return on Equity (MRQ)Greater than0.150.390
Return on Assets (MRQ)Greater than0.050.347
Total9/10 (90.0%)

3.4 Technical Score

Let's check the technical score of Neuren Pharmaceuticals Ltd based on Penke's default Symbol scanner.

Penke's Symbol Scanner

  
  
IndicatorConditionValue
RsiGreater than5063.093
Ma 20Greater thanMa 5013.533
Ma 50Greater thanMa 10013.340
Ma 100Greater thanMa 20012.526
OpenGreater thanClose14.940
Total4/5 (80.0%)

4. In-depth Analysis

4.1 About Neuren Pharmaceuticals Ltd

Neuren Pharmaceuticals Limited, a biopharmaceutical company, develops drugs for the treatment of neurological disorders. It develops and commercializes DAYBUE (trofinetide) for the treatment of Rett syndrome in adults and pediatric patients 2 years of age and older, as well as in Phase 2 clinical trial to treat Fragile X syndrome. The company also develops NNZ-2591, which has completed Phase 2 clinical trial for the treatment of Phelan-McDermid; and in Phase 2 clinical trial for the treatment of Angelman and Pitt Hopkins. In addition, it develops NNZ-2591, which is in Preclinical trial stage for the treatment of Prader-Willi syndrome. The company was incorporated in 2001 and is based in Camberwell, Australia.

Fundamental data was last updated by Penke on 2025-07-04 19:33:07.

4.2 In-depth Summary

4.2.1. Financial Health Summary

Profitability Details
 Compared to previous yearCompared to industry
The company is making a huge profit.
Using its assets, the company is very efficient in making profit.
Using its investors money, the company is very efficient in making profit.
Operating Efficiency Details
 Compared to previous yearCompared to industry
The company is operating very efficient.
The company is very efficient in keeping operating costs low.
Liquidity Details
 Compared to previous yearCompared to industry
The company is very able to pay all its short-term debts.
The company is very able to pay all its short-term debts with the most liquid assets.
Solvency Details
 Compared to previous yearCompared to industry
The company is very able to pay all its debts by selling its assets.
The company is very able to pay all its debts with equity.

4.2.2. Valuation Summary

Valuation Details
 Compared to previous yearCompared to industry
Based on the equity, the company is fair priced.
Based on the earnings, the company is underpriced.
Based on how much money comes from the company's main activities, the company is expensive.
3rd party ad coffee SUPPORTERis ad-free.

4.3 Financial Health

4.3.1. Profitability

4.3.1 Profitability
4.3.1.1. Net Profit Margin

Measures how much net profit Neuren Pharmaceuticals Ltd earns for each $1 of revenue.

  • Above 10% is considered healthy but always compare Neuren Pharmaceuticals Ltd to the Biotechnology industry mean.
  • A Net Profit Margin of 66.6% means that $0.67 for each $1 in revenue is generated as profit.

Let's take a look of the Net Profit Margin trends of Neuren Pharmaceuticals Ltd:

  • The MRQ is 66.6%. The company is making a huge profit. +2
  • The TTM is 66.6%. The company is making a huge profit. +2
Trends
Current periodCompared to+/- 
MRQ66.6%TTM66.6%0.0%
TTM66.6%YOY67.7%-1.1%
TTM66.6%5Y-278.1%+344.7%
5Y-278.1%10Y-421.5%+143.4%
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ66.6%-91.7%+158.3%
TTM66.6%-140.3%+206.9%
YOY67.7%-196.4%+264.1%
3Y45.2%-247.9%+293.1%
5Y-278.1%-343.3%+65.2%
10Y-421.5%-488.1%+66.6%
4.3.1.2. Return on Assets

Shows how efficient Neuren Pharmaceuticals Ltd is using its assets to generate profit.

  • Above 5% is considered healthy but always compare Neuren Pharmaceuticals Ltd to the Biotechnology industry mean.
  • 34.7% Return on Assets means that Neuren Pharmaceuticals Ltd generated $0.35 profit for each $1 in assets.

Let's take a look of the Return on Assets trends of Neuren Pharmaceuticals Ltd:

  • The MRQ is 34.7%. Using its assets, the company is very efficient in making profit. +2
  • The TTM is 34.7%. Using its assets, the company is very efficient in making profit. +2
Trends
Current periodCompared to+/- 
MRQ34.7%TTM34.7%0.0%
TTM34.7%YOY63.3%-28.7%
TTM34.7%5Y8.4%+26.2%
5Y8.4%10Y-27.6%+36.0%
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ34.7%-11.5%+46.2%
TTM34.7%-11.5%+46.2%
YOY63.3%-11.4%+74.7%
3Y32.8%-11.7%+44.5%
5Y8.4%-11.9%+20.3%
10Y-27.6%-13.7%-13.9%
4.3.1.3. Return on Equity

Shows how efficient Neuren Pharmaceuticals Ltd is using its investors money to generate profit.

  • Above 15%-20% is considered healthy but always compare Neuren Pharmaceuticals Ltd to the Biotechnology industry mean.
  • 39.0% Return on Equity means Neuren Pharmaceuticals Ltd generated $0.39 for each $1 the owners (shareholders) invested.

Let's take a look of the Return on Equity trends of Neuren Pharmaceuticals Ltd:

  • The MRQ is 39.0%. Using its investors money, the company is very efficient in making profit. +2
  • The TTM is 39.0%. Using its investors money, the company is very efficient in making profit. +2
Trends
Current periodCompared to+/- 
MRQ39.0%TTM39.0%0.0%
TTM39.0%YOY76.5%-37.5%
TTM39.0%5Y11.6%+27.4%
5Y11.6%10Y-36.8%+48.4%
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ39.0%-13.6%+52.6%
TTM39.0%-14.8%+53.8%
YOY76.5%-14.4%+90.9%
3Y38.7%-16.8%+55.5%
5Y11.6%-17.5%+29.1%
10Y-36.8%-19.5%-17.3%
3rd party ad coffee SUPPORTERis ad-free.

4.3.2. Operating Efficiency of Neuren Pharmaceuticals Ltd.

4.3.2. Operating Efficiency
4.3.2.1. Operating Margin

Measures how efficient Neuren Pharmaceuticals Ltd is operating .

  • Measures how much profit Neuren Pharmaceuticals Ltd makes for each $1 of sales after paying variable costs (production costs, wages, etc) but before taxes.
  • Above 15% is considered healthy but always compare Neuren Pharmaceuticals Ltd to the Biotechnology industry mean.
  • An Operating Margin of 82.3% means the company generated $0.82  for each $1 in revenue (before taxes).

Let's take a look of the Operating Margin trends of Neuren Pharmaceuticals Ltd:

  • The MRQ is 82.3%. The company is operating very efficient. +2
  • The TTM is 82.3%. The company is operating very efficient. +2
Trends
Current periodCompared to+/- 
MRQ82.3%TTM82.3%0.0%
TTM82.3%YOY85.9%-3.6%
TTM82.3%5Y-265.8%+348.1%
5Y-265.8%10Y-439.3%+173.5%
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ82.3%-221.8%+304.1%
TTM82.3%-250.7%+333.0%
YOY85.9%-208.5%+294.4%
3Y52.4%-220.2%+272.6%
5Y-265.8%-342.4%+76.6%
10Y-439.3%-462.5%+23.2%
4.3.2.2. Operating Ratio

Measures how efficient Neuren Pharmaceuticals Ltd is keeping operating costs low.

  • Below 1 is considered healthy (always compare to Biotechnology industry mean).
  • An Operation Ratio of 0.18 means that the operating costs are $0.18 for each $1 in net sales.

Let's take a look of the Operating Ratio trends of Neuren Pharmaceuticals Ltd:

  • The MRQ is 0.177. The company is very efficient in keeping operating costs low. +2
  • The TTM is 0.177. The company is very efficient in keeping operating costs low. +2
Trends
Current periodCompared to+/- 
MRQ0.177TTM0.1770.000
TTM0.177YOY0.256-0.080
TTM0.1775Y3.681-3.504
5Y3.68110Y6.833-3.152
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ0.1772.097-1.920
TTM0.1772.684-2.507
YOY0.2563.076-2.820
3Y0.5143.524-3.010
5Y3.6814.724-1.043
10Y6.8336.445+0.388
3rd party ad coffee SUPPORTERis ad-free.

4.4.3. Liquidity of Neuren Pharmaceuticals Ltd.

4.4.3. Liquidity
4.4.3.1. Current Ratio

Measures if Neuren Pharmaceuticals Ltd is able to pay off Short-term Debt.

  • Above 1.5 is considered healthy (always compare to Biotechnology industry mean).
  • A Current Ratio of 8.73 means the company has $8.73 in assets for each $1 in short-term debts.

Let's take a look of the Current Ratio trends of Neuren Pharmaceuticals Ltd:

  • The MRQ is 8.726. The company is very able to pay all its short-term debts. +2
  • The TTM is 8.726. The company is very able to pay all its short-term debts. +2
Trends
Current periodCompared to+/- 
MRQ8.726TTM8.7260.000
TTM8.726YOY5.780+2.947
TTM8.7265Y24.654-15.928
5Y24.65410Y18.236+6.418
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ8.7263.638+5.088
TTM8.7263.846+4.880
YOY5.7804.140+1.640
3Y13.4264.688+8.738
5Y24.6545.722+18.932
10Y18.2366.144+12.092
4.4.3.2. Quick Ratio

Measures if Neuren Pharmaceuticals Ltd is able to pay off Short-term Debt but only using the most liquid assets.

  • Above 1 is considered healthy but always compare Neuren Pharmaceuticals Ltd to the Biotechnology industry mean.
  • A Quick Ratio of 13.42 means the company can pay off $13.42 for each $1 in debt (using most liquid assets).

Let's take a look of the Quick Ratio trends of Neuren Pharmaceuticals Ltd:

  • The MRQ is 13.423. The company is very able to pay all its short-term debts with the most liquid assets. +2
  • The TTM is 13.423. The company is very able to pay all its short-term debts with the most liquid assets. +2
Trends
Current periodCompared to+/- 
MRQ13.423TTM13.4230.000
TTM13.423YOY10.626+2.797
TTM13.4235Y32.233-18.810
5Y32.23310Y24.399+7.834
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ13.4232.826+10.597
TTM13.4233.116+10.307
YOY10.6263.786+6.840
3Y16.2144.311+11.903
5Y32.2335.702+26.531
10Y24.3996.335+18.064
3rd party ad coffee SUPPORTERis ad-free.

4.5.4. Solvency of Neuren Pharmaceuticals Ltd.

4.5.4. Solvency
4.5.4.1. Debt to Asset Ratio

Measures how much % of Neuren Pharmaceuticals Ltd assets are financed with debt.

  • Below 1 (100%) is considered healthy but always compare Neuren Pharmaceuticals Ltd to Biotechnology industry mean.
  • A Debt to Asset Ratio of 0.11 means that Neuren Pharmaceuticals Ltd assets are financed with 11.2% credit (debt) and the remaining percentage (100% - 11.2%) is financed by its owners/shareholders. 

Let's take a look of the Debt to Asset Ratio trends of Neuren Pharmaceuticals Ltd:

  • The MRQ is 0.112. The company is very able to pay all its debts by selling its assets. +2
  • The TTM is 0.112. The company is very able to pay all its debts by selling its assets. +2
Trends
Current periodCompared to+/- 
MRQ0.112TTM0.1120.000
TTM0.112YOY0.172-0.061
TTM0.1125Y0.075+0.037
5Y0.07510Y0.105-0.030
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ0.1120.327-0.215
TTM0.1120.349-0.237
YOY0.1720.332-0.160
3Y0.1080.340-0.232
5Y0.0750.346-0.271
10Y0.1050.378-0.273
4.5.4.2. Debt to Equity Ratio

Measures if Neuren Pharmaceuticals Ltd is able to pay off its debts by using shareholders equity.

  • Below 2 is considered healthy but always compare Neuren Pharmaceuticals Ltd to the Biotechnology industry mean.
  • A Debt to Equity ratio of 12.6% means that company has $0.13 debt for each $1 in shareholders equity.

Let's take a look of the Debt to Equity Ratio trends of Neuren Pharmaceuticals Ltd:

  • The MRQ is 0.126. The company is very able to pay all its debts with equity. +2
  • The TTM is 0.126. The company is very able to pay all its debts with equity. +2
Trends
Current periodCompared to+/- 
MRQ0.126TTM0.1260.000
TTM0.126YOY0.208-0.083
TTM0.1265Y0.085+0.041
5Y0.08510Y0.130-0.045
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ0.1260.383-0.257
TTM0.1260.438-0.312
YOY0.2080.414-0.206
3Y0.1250.450-0.325
5Y0.0850.457-0.372
10Y0.1300.512-0.382
3rd party ad coffee SUPPORTERis ad-free.

4.6. Market Valuation

4.6.1. Earnings Per Share
4.6.2.1. Price to Earnings Ratio

Measures how much money you pay for each share for every $1 in earnings Neuren Pharmaceuticals Ltd generates.

  • Above 15 is considered overpriced but always compare Neuren Pharmaceuticals Ltd to the Biotechnology industry mean.
  • A PE ratio of 11.51 means the investor is paying $11.51 for every $1 in earnings.

Let's take a look of the Price to Earnings Ratio trends of Neuren Pharmaceuticals Ltd:

  • The EOD is 13.415. Based on the earnings, the company is underpriced. +1
  • The MRQ is 11.509. Based on the earnings, the company is underpriced. +1
  • The TTM is 11.509. Based on the earnings, the company is underpriced. +1
Trends
Current periodCompared to+/- 
EOD13.415MRQ11.509+1.906
MRQ11.509TTM11.5090.000
TTM11.509YOY20.787-9.278
TTM11.5095Y1,104.690-1,093.182
5Y1,104.69010Y567.289+537.401
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
EOD13.415-2.399+15.814
MRQ11.509-2.092+13.601
TTM11.509-2.625+14.134
YOY20.787-3.784+24.571
3Y1,867.335-3.762+1,871.097
5Y1,104.690-6.363+1,111.053
10Y567.289-7.055+574.344
4.6.2.2. Price To Free Cash Flow Ratio

Let's take a look of the Price To Free Cash Flow Ratio trends of Neuren Pharmaceuticals Ltd:

  • The EOD is -168.924. Based on how much money comes from the company's main activities, the company is expensive. -2
  • The MRQ is -144.924. Based on how much money comes from the company's main activities, the company is expensive. -2
  • The TTM is -144.924. Based on how much money comes from the company's main activities, the company is expensive. -2
Trends
Current periodCompared to+/- 
EOD-168.924MRQ-144.924-23.999
MRQ-144.924TTM-144.9240.000
TTM-144.924YOY17.661-162.585
TTM-144.9245Y18.276-163.200
5Y18.27610Y1.842+16.434
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
EOD-168.924-3.299-165.625
MRQ-144.924-2.742-142.182
TTM-144.924-3.801-141.123
YOY17.661-4.402+22.063
3Y53.000-5.140+58.140
5Y18.276-8.483+26.759
10Y1.842-9.296+11.138
3rd party ad coffee SUPPORTERis ad-free.
4.6.2. Book Value per Share
4.6.2.1. Price to Book Ratio

Measures if the stock price of Neuren Pharmaceuticals Ltd is to cheap or to expensive compared to its book value.

  • At or below 1 is considered healthy (always compare to Biotechnology industry mean).
  • A PB ratio of 4.49 means the investor is paying $4.49 for each $1 in book value.

Let's take a look of the Price to Book Ratio trends of Neuren Pharmaceuticals Ltd:

  • The EOD is 5.236. Based on the equity, the company is overpriced. -1
  • The MRQ is 4.492. Based on the equity, the company is fair priced.
  • The TTM is 4.492. Based on the equity, the company is fair priced.
Trends
Current periodCompared to+/- 
EOD5.236MRQ4.492+0.744
MRQ4.492TTM4.4920.000
TTM4.492YOY15.912-11.420
TTM4.4925Y12.767-8.275
5Y12.76710Y12.094+0.673
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
EOD5.2362.113+3.123
MRQ4.4921.856+2.636
TTM4.4922.125+2.367
YOY15.9122.454+13.458
3Y15.0152.492+12.523
5Y12.7673.668+9.099
10Y12.0944.364+7.730
4.6.2. Total Gains per Share

4.7 Holders & Insider Transactions

Let's take a look at which institutions, funds and insiders are holding shares of Neuren Pharmaceuticals Ltd.

3rd party ad coffee SUPPORTERis ad-free.

5. Financial Statements




5.1. Reversals in quarterly reports

I have detected a reversal (positive to negative, negative to positive) in the following values of the quarterly reports.

 2020-12-312021-12-312022-12-312023-12-312024-12-31
Accumulated Other Comprehensive Income  -10,284836-9,4481,990-7,4581,150-6,30824,51118,203
Long-term Assets Other  -10-2-12-9-2121010,34810,348



5.2. Latest Balance Sheet

Balance Sheet of 2024-12-31. Currency in AUD. All numbers in thousands.

Summary
Total Assets409,706
Total Liabilities45,802
Total Stockholder Equity363,904
 As reported
Total Liabilities 45,802
Total Stockholder Equity+ 363,904
Total Assets = 409,706

Assets

Total Assets409,706
Total Current Assets399,327
Long-term Assets10,379
Total Current Assets
Cash And Cash Equivalents 3,153
Short-term Investments 219,089
Net Receivables 172,910
Other Current Assets 4,175
Total Current Assets  (as reported)399,327
Total Current Assets  (calculated)399,327
+/-0
Long-term Assets
Property Plant Equipment 31
Long-term Assets Other 10,348
Long-term Assets  (as reported)10,379
Long-term Assets  (calculated)10,379
+/-0

Liabilities & Shareholders' Equity

Total Current Liabilities45,761
Long-term Liabilities41
Total Stockholder Equity363,904
Total Current Liabilities
Accounts payable 1,449
Other Current Liabilities 44,312
Total Current Liabilities  (as reported)45,761
Total Current Liabilities  (calculated)45,761
+/-0
Long-term Liabilities
Long-term Liabilities  (as reported)41
Long-term Liabilities  (calculated)0
+/- 41
Total Stockholder Equity
Common Stock165,270
Retained Earnings 180,431
Accumulated Other Comprehensive Income 18,203
Total Stockholder Equity (as reported)363,904
Total Stockholder Equity (calculated)363,904
+/-0
Other
Capital Stock165,270
Cash and Short Term Investments 222,242
Common Stock Shares Outstanding 130,780
Liabilities and Stockholders Equity 409,706
Net Debt -3,153
Net Invested Capital 363,904
Net Working Capital 353,566
Property Plant and Equipment Gross 31



5.3. Balance Sheets Structured

Currency in AUD. All numbers in thousands.

 Trend2024-12-312023-12-312022-12-312021-12-312020-12-312019-12-312018-12-312017-12-312016-12-312015-12-312014-12-312013-12-312012-12-312011-12-312010-12-312009-12-312008-12-312007-12-312006-12-312005-12-312004-12-312003-12-312002-12-312001-12-312000-12-31
> Total Assets 
4,584
5,149
3,332
696
12,962
35,205
19,524
14,586
8,545
10,285
5,717
11,137
8,482
26,413
22,106
16,904
6,210
17,944
26,642
14,406
24,953
40,056
43,267
247,970
409,706
409,706247,97043,26740,05624,95314,40626,64217,9446,21016,90422,10626,4138,48211,1375,71710,2858,54514,58619,52435,20512,9626963,3325,1494,584
   > Total Current Assets 
0
0
0
0
2,174
25,035
10,350
1,281
1,522
5,263
1,812
7,594
5,267
25,997
21,787
16,676
6,053
16,086
26,639
14,396
24,943
40,044
43,246
247,156
399,327
399,327247,15643,24640,04424,94314,39626,63916,0866,05316,67621,78725,9975,2677,5941,8125,2631,5221,28110,35025,0352,1740000
       Cash And Cash Equivalents 
4,109
3,773
1,928
116
317
11,675
9,459
1,137
1,354
3,426
1,485
7,489
5,137
24,336
20,824
16,642
5,051
4,706
23,576
13,844
24,188
36,783
40,180
17,094
3,153
3,15317,09440,18036,78324,18813,84423,5764,7065,05116,64220,82424,3365,1377,4891,4853,4261,3541,1379,45911,6753171161,9283,7734,109
       Short-term Investments 
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
2,272
10,688
2,121
13,024
23,959
0
0
211,445
219,089
219,089211,4450023,95913,0242,12110,6882,2720000000000000000
       Net Receivables 
0
0
180
16
982
1,561
792
112
93
281
43
18
11
1,563
912
10
1,002
44
423
552
755
1,424
1,089
14,412
172,910
172,91014,4121,0891,424755552423441,002109121,563111843281931127921,5619821618000
       Inventory 
0
0
0
0
30
12,103
0
0
0
-1,557
-284
-87
-119
0
0
0
-1,002
0
0
-539
-755
0
0
0
0
0000-755-53900-1,002000-119-87-284-1,55700012,103300000
   > Long-term Assets 
0
0
0
0
10,788
10,169
9,174
13,305
7,022
5,022
3,906
3,543
3,215
416
319
228
157
80
3
10
10
12
21
814
10,379
10,379814211210103801572283194163,2153,5433,9065,0227,02213,3059,17410,16910,7880000
       Property Plant Equipment 
329
885
860
0
66
80
270
300
79
41
17
5
25
23
29
11
12
7
2
10
10
12
21
43
31
314321121010271211292325517417930027080660860885329
       Long Term Investments 
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
1,374
0
0
0
0
0
0
0
00000001,37400000000000000000
       Intangible Assets 
0
0
0
0
10,722
10,089
8,903
13,005
6,944
4,981
3,888
3,538
3,189
393
290
217
145
73
1
0
0
0
0
0
0
0000001731452172903933,1893,5383,8884,9816,94413,0058,90310,08910,7220000
       Other Assets 
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
1,778
0
0
0
0
0
0
0
00000001,77800000000000000000
> Total Liabilities 
7,616
16,781
1,509
15,413
4,196
3,046
3,377
7,035
2,972
2,937
2,184
1,684
2,141
2,058
3,028
2,502
2,027
1,580
1,973
559
753
803
1,678
42,763
45,802
45,80242,7631,6788037535591,9731,5802,0272,5023,0282,0582,1411,6842,1842,9372,9727,0353,3773,0464,19615,4131,50916,7817,616
   > Total Current Liabilities 
614
1,476
1,509
1,689
4,196
3,046
3,310
6,958
2,934
2,522
2,177
1,684
2,128
2,058
3,028
2,502
2,027
1,580
1,973
559
753
803
1,678
42,763
45,761
45,76142,7631,6788037535591,9731,5802,0272,5023,0282,0582,1281,6842,1772,5222,9346,9583,3103,0464,1961,6891,5091,476614
       Short-term Debt 
0
0
0
0
0
0
13
3,463
23
9
454
0
0
0
0
0
0
9,138
0
0
0
0
0
0
0
00000009,1380000004549233,46313000000
       Accounts payable 
216
815
1,102
615
1,091
1,198
2,188
1,301
1,896
1,977
1,331
1,214
1,720
1,849
2,755
1,771
1,035
723
1,335
340
167
245
258
675
1,449
1,4496752582451673401,3357231,0351,7712,7551,8491,7201,2141,3311,9771,8961,3012,1881,1981,0916151,102815216
       Other Current Liabilities 
398
661
407
674
3,105
1,848
1,109
2,194
1,015
536
400
469
408
209
273
731
992
857
638
219
586
558
1,420
4,969
44,312
44,3124,9691,4205585862196388579927312732094084694005361,0152,1941,1091,8483,105674407661398
   > Long-term Liabilities 
0
0
0
0
1,093
1,198
67
78
38
414
7
1,214
13
1,849
0
0
0
0
0
340
167
245
258
0
41
410258245167340000001,849131,21474143878671,1981,0930000
       Other Liabilities 
0
0
0
0
0
0
75
60
34
22
9
0
17
0
0
0
0
0
0
0
0
0
0
0
0
000000000000170922346075000000
> Total Stockholder Equity
0
0
1,823
0
8,735
19,884
16,147
7,551
5,573
7,490
3,574
9,498
6,484
24,559
19,299
14,402
4,183
16,364
24,669
13,847
24,200
39,253
41,589
205,207
363,904
363,904205,20741,58939,25324,20013,84724,66916,3644,18314,40219,29924,5596,4849,4983,5747,4905,5737,55116,14719,8848,73501,82300
   Common Stock
0
0
0
0
19,529
39,115
44,528
47,581
57,522
56,131
52,280
61,144
64,177
101,997
104,363
111,912
112,829
121,136
126,426
126,426
145,567
167,578
167,740
173,127
165,270
165,270173,127167,740167,578145,567126,426126,426121,136112,829111,912104,363101,99764,17761,14452,28056,13157,52247,58144,52839,11519,5290000
   Retained Earnings Total Equity0000000000000000000000000
   Accumulated Other Comprehensive Income 
0
0
0
0
-277
-325
522
676
2,129
2,915
4,545
6,361
7,878
9,854
-916
-7,764
-7,818
-7,332
-8,497
-8,503
-10,284
-9,448
-7,458
-6,308
18,203
18,203-6,308-7,458-9,448-10,284-8,503-8,497-7,332-7,818-7,764-9169,8547,8786,3614,5452,9152,129676522-325-2770000
   Capital Surplus 0000000000000000000000000
   Treasury Stock0000000000000000000000000
   Other Stockholders Equity 
0
0
0
0
0
0
0
0
0
0
0
0
0
11,579
-916
-7,764
-10,292
-7,332
-8,497
-8,503
-10,284
-9,448
-10,680
0
0
00-10,680-9,448-10,284-8,503-8,497-7,332-10,292-7,764-91611,5790000000000000



5.4. Balance Sheets

Currency in AUD. All numbers in thousands.




5.5. Cash Flows

Currency in AUD. All numbers in thousands.




5.6. Income Statements

Currency in AUD. All numbers in thousands.


5.7. Latest Income Statement

Income Statement (annual), 2024-12-31. Currency in AUD. All numbers in thousands.

Gross Profit (+$)
totalRevenue213,243
Cost of Revenue-22
Gross Profit213,221213,221
 
Operating Income (+$)
Gross Profit213,221
Operating Expense-37,671
Operating Income175,550175,550
 
Operating Expense (+$)
Research Development32,970
Selling General Administrative4,701
Selling And Marketing Expenses-
Operating Expense37,67137,671
 
Net Interest Income (+$)
Interest Income11,014
Interest Expense--
Other Finance Cost-0
Net Interest Income11,014
 
Pretax Income (+$)
Operating Income175,550
Net Interest Income11,014
Other Non-Operating Income Expenses-
Income Before Tax (EBT)182,940168,160
EBIT - interestExpense = 175,550
182,940
142,043
Interest Expense-
Earnings Before Interest and Taxes (EBIT)175,550182,940
Earnings Before Interest and Taxes (EBITDA)175,572
 
After tax Income (+$)
Income Before Tax182,940
Tax Provision-40,897
Net Income From Continuing Ops142,043142,043
Net Income142,043
Net Income Applicable To Common Shares-
 
Non-recurring Events
Discontinued Operations-
Extraordinary Items-
Effect of Accounting Charges-
Other Items-
Non Recurring-
Other Operating Expenses37,693
Total Other Income/Expenses Net7,390-11,014
 

Technical Analysis of Neuren Pharmaceuticals Ltd
The psychology behind the price

Technical indicators reflecting market sentiment and the collective psychology of you and other traders. Your emotions and other traders' emotions, such as fear and greed, play a significant role in driving price movements.

General trend

First of all, I'm going to put something in the back of your mind. One of the most stable factors that gives you more confidence as a trader: the general trend of Neuren Pharmaceuticals Ltd. The general trend of Neuren Pharmaceuticals Ltd is BULLISH with 85.7% confidence. It is very important for your mental being to use each indicator with this in mind. But beware, also the general trend flips once in a while! You can use moving averages to determine Neuren Pharmaceuticals Ltd's overall trend. For convenience I use the most commonly used moving averages: 20, 50, 100 & 200. Of course you can use other moving averages or other indicators to determine the trend.

Indicator phases

Some of the indicators I use have 3 zones: overbought, oversold and neutral. Transitions between these zones (market phases) provide valuable trading signals and insights. Expecially with the general trend mind, I use the highlighted phases:

Indicator zone transitionsBullish trend (85.7%) Bearish trend (-85.7%)
Overbought to neutralBullish pullback=Bearish reversal
Upper to lower neutralBullish correction=Bearish continuation
Nuetral to oversoldOversold=Oversold
Oversold to neutralBullish reversal=Bearish correction
Lower to upper neutralBullish continuation=Bearish pullback
Nuetral to overboughtOverbought=Overbought

1. Neuren Pharmaceuticals Ltd Price Targets

1.1 Support & Resistance

Support and resistance are levels on a price chart that act as barriers or zones where the price of an asset tends to stop, reverse, or experience a significant amount of buying or selling pressure.

Support is a price level at which demand for an asset is strong enough to prevent the price from falling further.
Resistance is a price level at which selling pressure becomes significant enough to prevent the price of an asset from rising further.


Score

Let's take a look at the Support & Resistance of Neuren Pharmaceuticals Ltd.

The long score for the Support & Resistance is 1/1.
The longshort score for the Support & Resistance is 1/(-1 +1).

  • Around support: The price is currently trading around a support level. This can be considered as a potential entry level. +1

The bullish price targets are: 17.94 < 17.97 < 18.16.

The bearish price targets are: 14.83 > 14.71 > 14.50.

Know someone who trades $NEU? Share this with them.👇

Neuren Pharmaceuticals Ltd Daily Support & Resistance Chart
3rd party ad coffee SUPPORTERis ad-free.

2. Trend Indicators

2.1 Moving Averages

Shows the moving average of the selected period.

  • Moving averages are lagging trend indicators.
  • There are many types of moving averages.
  • Moving averages are also used within other indicators.

Score

Let's take a look at the Moving Averages of Neuren Pharmaceuticals Ltd. The current mas is .

The long score for the Moving Averages is 13/14.
The longshort score for the Moving Averages is 12/(-14 +14).

  • MA 20 trending up: The MA 20 is trending up. +1
  • Close > MA 20: The price is above the MA 20. +1
  • MA 20 > MA 50: The MA 20 is higher than the MA 50. +1
  • MA 20 > MA 100: The MA 20 is higher than the MA 100. +1
  • MA 20 > MA 200: The MA 20 is higher than the MA 200. +1
  • MA 50 trending up: The MA 50 is trending up. +1
  • Close > MA 50: The price is above the MA 50. +1
  • MA 50 > MA 100: The MA 50 is higher than the MA 100. +1
  • MA 50 > MA 200: The MA 50 is higher than the MA 200. +1
  • MA 100 trending up: The MA 100 is trending up. +1
  • Close > MA 100: The price is above the MA 100. +1
  • MA 100 < MA 200: The MA 100 is lower than the MA 200. -1
  • MA 200 trending up: The MA 200 is trending up. +1
  • Close > MA 200: The price is above the MA 200. +1

Directionalities and relatives.

Moving AverageAmount of candlesTrendPrice +/-vs. MA 50vs. MA 100vs. MA 200
MA 2020
MA 5050-
MA 100100--
MA 200200---

Explanation: https://www.youtube.com/watch?v=xwW8h0lrQ-I

Neuren Pharmaceuticals Ltd Daily Moving Averages Chart
2.2 Moving Average Convergence/Divergence (MACD)

Shows the momentum of the selected period based on two moving averages.

  • MACD is a lagging momentum indicator.
  • Uses two moving averages.
  • Can show buy or sell signals based on momentum.
  • Can show overbought. and oversold. levels.

Score

Let's take a look at the Moving Average Convergence/Divergence (MACD) of Neuren Pharmaceuticals Ltd. The current macd is 0.35767636.

The long score for the Moving Average Convergence/Divergence (MACD) is 4/4.
The longshort score for the Moving Average Convergence/Divergence (MACD) is 4/(-4 +4).

  • MACD line > signal line: The MACD line is above the signal line, which indicates a bullish signal in the market. This means that the positive momentum is currently stronger than the average momentum, suggesting that buyers are more active than sellers, and there's a higher probability of the Neuren Pharmaceuticals Ltd price going up in the near term. +2
  • MACD > 0: The MACD is above the zero line (centerline), it indicates a bullish signal for Neuren Pharmaceuticals Ltd. This means that the short-term moving average is higher than the long-term moving average, signaling positive momentum and suggesting a higher likelihood of the Neuren Pharmaceuticals Ltd price continuing to rise in the near future. It indicates that buyers are gaining control, and there is optimism in the market, leading to potential price increases. +1
  • Trending up: The MACD line is trending up. This indicates that the short-term moving average is rising faster than the long-term moving average, suggesting positive momentum in the market. This signals that buyers are becoming more active and confident, leading to potential price increases as traders anticipate further gains and are willing to buy at higher prices. +1
Neuren Pharmaceuticals Ltd Daily Moving Average Convergence/Divergence (MACD) ChartNeuren Pharmaceuticals Ltd Daily Moving Average Convergence/Divergence (MACD) Chart
2.3 Directional Movement Index (DMI)

The DMI is a collection of 3 indicators: +DI (Plus Direction Indicator), -DI (Minus Direction Indicator) and ADX (Average Directional Index). The ADX helps you determine the strength of a trend.


Score

Let's take a look at the Directional Movement Index (DMI) of Neuren Pharmaceuticals Ltd. The current adx is 23.72.

The long score for the Directional Movement Index (DMI) is 2/7.
The longshort score for the Directional Movement Index (DMI) is 2/(-7 +7).

  • PLUS_ID > MINUS_DI: The +DI line is above the -DI line. This indicates a bullish signal in the market, as the positive directional movement is currently stronger than the negative directional movement, showing that buyers have the upper hand. Market psychology suggests that traders are optimistic, expecting further price increases, and are more willing to buy Neuren Pharmaceuticals Ltd shares, leading to potential upward momentum in its price. +1
  • PLUS_ID > MINUS_DI && ADX < 25 && ADX trending up: The ADX is below 25 and indicates a weak or no trend. However, the ADX is rising and a new bullish trend could be forming. +1
Neuren Pharmaceuticals Ltd Daily Directional Movement Index (DMI) Chart
2.4 Parabolic SAR

Shows the current trend and potential entry and exit signals.

  • Parabolic SAR (stop and reverse) is a lagging trend indicator.
  • Shows the current trend.
  • Shows potential entry signals.
  • Shows  potential exit signals.
  • Can be used to place trailing stoplosses..

Score

Let's take a look at the Parabolic SAR of Neuren Pharmaceuticals Ltd. The current sar is 13.20.

The long score for the Parabolic SAR is 1/1.
The longshort score for the Parabolic SAR is 1/(-1 +1).

  • Close > SAR: The price is above the SAR. It's generally considered a bullish signal. +1
Neuren Pharmaceuticals Ltd Daily Parabolic SAR Chart
3rd party ad coffee SUPPORTERis ad-free.

3. Momentum Indicators

3.1 Relative Strength Index (RSI)

Measures the speed and change of price movements.

  • Leading momentum indicator, meaning the signals are instant.
  • Ranges between 0 and 100.
  • Above 70 is considered overbought.
  • Below 30 is considered oversold.
  • Above or below 50 can also be used to determine price trend or support and resistance.
  • RSI divergence looks at a deviation between RSI and price movement. Penketrading automatically calculates RSI divergences.
  • Can be used in many different ways

Score

Let's take a look at the Relative Strength Index (RSI) of Neuren Pharmaceuticals Ltd. The current rsi is 63.09. The current phase is Continuation in bull market.

The long score for the Relative Strength Index (RSI) is 3/13.
The longshort score for the Relative Strength Index (RSI) is 2/(-13 +13).

  • Continuation in bull market: Uptrend continues after a consolidation or pullback. Hold or add to existing positions.
  • Trending down: The RSI is trending down. -1
Neuren Pharmaceuticals Ltd Daily Relative Strength Index (RSI) ChartNeuren Pharmaceuticals Ltd Daily Relative Strength Index (RSI) Chart
3.2 Stochastic Oscillator

Compares a certain price to multiple prices ranging over time.

  • Leading momentum indicator, meaning the signals are instant.
  • Used to determine overbought and oversold areas much like the RSI.
  • Ranges between 0 and 100.
  • Above 80 is considered overbought.
  • Below 20 is considered oversold.
  • Consists of two lines named K and D.
  • K compares the highest high and lowest low on the selected price range.
  • The D line is a moving average of the K line.
  • Can be used to spot divergences

Score

Let's take a look at the Stochastic Oscillator of Neuren Pharmaceuticals Ltd. The current phase is Continuation in bull market.

The long score for the Stochastic Oscillator is 1/6.
The longshort score for the Stochastic Oscillator is -2/(-6 +6).

  • STOCH > 50: The STOCH %K is above 50. There are more buyers than sellers. +1
  • STOCH %K line < STOCH %D line: The STOCH %K line is below the STOCH %D line, which indicates a bearish signal in the market. This means that the negative momentum is currently stronger than the average momentum, suggesting that sellers are more active than buyers, and there's a higher probability of the Neuren Pharmaceuticals Ltd price going down in the near term. -2
  • Trending down: The STOCH %K is trending down. -1
Neuren Pharmaceuticals Ltd Daily Stochastic Oscillator ChartNeuren Pharmaceuticals Ltd Daily Stochastic Oscillator Chart
3.3 Commodity Channel Index (CCI)

Measures the difference between the current price and the historical average price.

  • Lagging or leading Momentum indicator
  • When the CCI is above zero, the price is above the historical average
  • When the CCI is below zero, the price is below the historical average
  • Used for spotting trends
    • If the CCI moves from negative or near zero to positive 100 that might indicate an uptrend
    • If the CCI moves from positive or near zero to negative -100 that might indicate a downtrend

Score

Let's take a look at the Commodity Channel Index (CCI) of Neuren Pharmaceuticals Ltd. The current cci is 111.70.

The long score for the Commodity Channel Index (CCI) is 1/1.
The longshort score for the Commodity Channel Index (CCI) is 1/(-1 +1).

  • CCI > 100: The CCI is above 100, it indicates that the price is significantly above its average, suggesting a potential overbought condition. +1
Neuren Pharmaceuticals Ltd Daily Commodity Channel Index (CCI) ChartNeuren Pharmaceuticals Ltd Daily Commodity Channel Index (CCI) Chart
3.4 Chande Momentum Oscillator (CMO)

Measures the difference between the sum of recent gains and the sum of recent losses. Then divides the result by the sum of all price movements in that period.

  • Lagging momentum indicator
  • Ranges between +100 and -100
  • Considered overbought above +50
  • Considered oversold below -50
  • It's possible to add a moving average that acts as a signal line

Score

Let's take a look at the Chande Momentum Oscillator (CMO) of Neuren Pharmaceuticals Ltd. The current cmo is 33.56.

The long score for the Chande Momentum Oscillator (CMO) is 1/1.
The longshort score for the Chande Momentum Oscillator (CMO) is 1/(-1 +1).

  • CMO > 0: The CMO is above 0, the momentum of the price is positive, indicating a potential uptrend in the price. +1
Neuren Pharmaceuticals Ltd Daily Chande Momentum Oscillator (CMO) ChartNeuren Pharmaceuticals Ltd Daily Chande Momentum Oscillator (CMO) Chart
3.5 Williams %R

 Shows the current price relative to the highest high over the last 14 days.
 

  • Lagging momentum indicator
  • Ranging between 0 and -100
  • Above -20 is considered overbought
  • Below -80 is considered oversold
  • Is prone to give false signals

Score

Let's take a look at the Williams %R of Neuren Pharmaceuticals Ltd. The current willr is -21.16040956.

The long score for the Williams %R is 0/1.
The longshort score for the Williams %R is 0/(-1 +1).

  • WILLR between -80 and -20: The Williams %R is between -80 and -20. This indicates that Neuren Pharmaceuticals Ltd is trading in a neutral price range, neither oversold nor overbought, suggesting a balanced market condition without any extreme price signals.
Neuren Pharmaceuticals Ltd Daily Williams %R ChartNeuren Pharmaceuticals Ltd Daily Williams %R Chart
3rd party ad coffee SUPPORTERis ad-free.

4. Volatility Indicators

4.1 Bollinger Bands

Shows if the price is to high or to low relative to an average.

  • Lagging volatility indicator
  • Uses 3 bands: one upper, one lower and one in the middle
  • Works best when the middle band reflects an intermediate trend (MA20).
  • When the price is moving closer to the upper band, the market might be overbought
  • When the price is moving closer to the lower band, the market might be oversold 

Score

Let's take a look at the Bollinger Bands of Neuren Pharmaceuticals Ltd.

Neuren Pharmaceuticals Ltd Daily Bollinger Bands Chart
4.2 Average True Range (ATR)
Measures market volatility
  • Leading volatility indicator
  • Can be used to determine stop-loss positions
  • Calculated by:
    • Current high minus the current low
    • Current high minus the previous close
    • Current low minus the previous close
  • The larger the range of the candles, the greater the ATR value

Score

Let's take a look at the Average True Range (ATR) of Neuren Pharmaceuticals Ltd. The current atr is 0.60513508.

Neuren Pharmaceuticals Ltd Daily Average True Range (ATR) ChartNeuren Pharmaceuticals Ltd Daily Average True Range (ATR) Chart
3rd party ad coffee SUPPORTERis ad-free.

5. Volume Indicators

5.1 On-Balance Volume (OBV)

 Measures market volatility

  • Leading momentum indicator
  • Calculation:
    • If the closing price is above the previous closing price: OBV = previous OBV + current volume
    • If the closing price is below the previous closing price: OBV = previous OBV - current volume
    • If the closing price is the same as the previous closing price than the OBV is the same.
  • Can be used to confirm price trends
  • Can be used with divergences

Score

Let's take a look at the On-Balance Volume (OBV) of Neuren Pharmaceuticals Ltd. The current obv is -5,556,301.

Neuren Pharmaceuticals Ltd Daily On-Balance Volume (OBV) ChartNeuren Pharmaceuticals Ltd Daily On-Balance Volume (OBV) Chart
5.2 Money Flow Index (MFI)

Measures the flow of money in and out of a security

  • Lagging momentum indicator
  • Looks like RSI but uses volume as an extra metric (RSI only considers price)
  • Above 80 is considered overbought
  • Below 20 is considered oversold
  • Can be used with divergences

Score

Let's take a look at the Money Flow Index (MFI) of Neuren Pharmaceuticals Ltd. The current mfi is 76.04.

The long score for the Money Flow Index (MFI) is 1/2.
The longshort score for the Money Flow Index (MFI) is 1/(-2 +2).

  • MFI > 50: +1
Neuren Pharmaceuticals Ltd Daily Money Flow Index (MFI) ChartNeuren Pharmaceuticals Ltd Daily Money Flow Index (MFI) Chart
3rd party ad coffee SUPPORTERis ad-free.

6. Summary

6.1. Notifications

TypeNotificationDate
PenkeCurrently no notifications for Neuren Pharmaceuticals Ltd.

6.2. Trading Signals

Below you will find trading signals as the indicator is commonly used. This doesn't mean you should use it that way. Learn from these, but don't use them blindly. I recommend using at least 4 indicators, 1 from each category: trend, momentum, volatility and volume.

DateIndicatorSignal
2025-02-19DMI LONG ENTRY SHORT CLOSEThe +DI crossed the -DI to the upside. The trend is reversing to an up trend.
STOCH SHORT EXITThe %K line crosses above the %D line.
CMO LONG ENTRY SHORT CLOSEZero line crossover to upside
2025-02-20DMI SHORT ENTRY LONG CLOSEThe +DI crossed the -DI to the downside. The trend is reversing to a down trend.
CMO SHORT ENTRY LONG CLOSEZero line crossover to downside
WILLR SHORT ENTRY LONG CLOSE-80 crossover to downside
2025-02-24DMI LONG ENTRY SHORT CLOSEThe +DI crossed the -DI to the upside. The trend is reversing to an up trend.
SAR LONG ENTRY SHORT CLOSEThe price broke the SAR to the upside.
CMO LONG ENTRY SHORT CLOSEZero line crossover to upside
2025-02-25STOCH LONG EXITThe %K line crosses below the %D line.
CMO SHORT ENTRY LONG CLOSEZero line crossover to downside
2025-02-26WILLR SHORT ENTRY LONG CLOSE-80 crossover to downside
2025-02-27MACD LONG ENTRY SHORT CLOSEThe MACD line crosses above the signal line.
STOCH SHORT EXITThe %K line crosses above the %D line.
CMO LONG ENTRY SHORT CLOSEZero line crossover to upside
WILLR LONG ENTRY SHORT CLOSE-20 crossover to upside
ATR LONG ENTRY SHORT CLOSEPrice closed above (close + ATR).
2025-02-28MACD SHORT ENTRY LONG CLOSEThe MACD line crosses below the signal line.
SAR SHORT ENTRY LONG CLOSEThe price broke the SAR to the downside
STOCH LONG EXITThe %K line crosses below the %D line.
CMO SHORT ENTRY LONG CLOSEZero line crossover to downside
ATR SHORT ENTRY LONG CLOSEPrice closed below (close - ATR).
2025-03-03DMI SHORT ENTRY LONG CLOSEThe +DI crossed the -DI to the downside. The trend is reversing to a down trend.
CCI SHORT ENTRY LONG CLOSE-100 crossover to downside
2025-03-04WILLR SHORT ENTRY LONG CLOSE-80 crossover to downside
BB LONG ENTRY SHORT CLOSEPrice closed below the lower band.
ATR SHORT ENTRY LONG CLOSEPrice closed below (close - ATR).
2025-03-06STOCH SHORT EXITThe %K line crosses above the %D line.
2025-03-07STOCH LONG EXITThe %K line crosses below the %D line.
WILLR SHORT ENTRY LONG CLOSE-80 crossover to downside
2025-03-11BB LONG ENTRY SHORT CLOSEPrice closed below the lower band.
ATR SHORT ENTRY LONG CLOSEPrice closed below (close - ATR).
2025-03-14STOCH SHORT EXITThe %K line crosses above the %D line.
ATR LONG ENTRY SHORT CLOSEPrice closed above (close + ATR).
2025-03-18DMI LONG ENTRY SHORT CLOSEThe +DI crossed the -DI to the upside. The trend is reversing to an up trend.
SAR LONG ENTRY SHORT CLOSEThe price broke the SAR to the upside.
CMO LONG ENTRY SHORT CLOSEZero line crossover to upside
2025-03-19CMO SHORT ENTRY LONG CLOSEZero line crossover to downside
2025-03-20MACD LONG ENTRY SHORT CLOSEThe MACD line crosses above the signal line.
CMO LONG ENTRY SHORT CLOSEZero line crossover to upside
2025-03-24WILLR LONG ENTRY SHORT CLOSE-20 crossover to upside
2025-03-26DMI SHORT ENTRY LONG CLOSEThe +DI crossed the -DI to the downside. The trend is reversing to a down trend.
STOCH LONG EXITThe %K line crosses below the %D line.
CMO SHORT ENTRY LONG CLOSEZero line crossover to downside
ATR SHORT ENTRY LONG CLOSEPrice closed below (close - ATR).
2025-03-28STOCH SHORT EXITThe %K line crosses above the %D line.
2025-03-31SAR SHORT ENTRY LONG CLOSEThe price broke the SAR to the downside
STOCH LONG EXITThe %K line crosses below the %D line.
2025-04-01MACD SHORT ENTRY LONG CLOSEThe MACD line crosses below the signal line.
WILLR SHORT ENTRY LONG CLOSE-80 crossover to downside
2025-04-02CCI SHORT ENTRY LONG CLOSE-100 crossover to downside
BB LONG ENTRY SHORT CLOSEPrice closed below the lower band.
2025-04-04STOCH SHORT EXITThe %K line crosses above the %D line.
ATR SHORT ENTRY LONG CLOSEPrice closed below (close - ATR).
2025-04-07ATR SHORT ENTRY LONG CLOSEPrice closed below (close - ATR).
2025-04-09STOCH LONG EXITThe %K line crosses below the %D line.
2025-04-10RSI LONG ENTRY SHORT CLOSE30 crossover to upside
STOCH SHORT EXITThe %K line crosses above the %D line.
ATR LONG ENTRY SHORT CLOSEPrice closed above (close + ATR).
2025-04-11WILLR SHORT ENTRY LONG CLOSE-80 crossover to downside
2025-04-14SAR LONG ENTRY SHORT CLOSEThe price broke the SAR to the upside.
CMO LONG ENTRY SHORT CLOSEZero line crossover to upside
ATR LONG ENTRY SHORT CLOSEPrice closed above (close + ATR).
2025-04-15MACD LONG ENTRY SHORT CLOSEThe MACD line crosses above the signal line.
DMI LONG ENTRY SHORT CLOSEThe +DI crossed the -DI to the upside. The trend is reversing to an up trend.
2025-04-16DMI SHORT ENTRY LONG CLOSEThe +DI crossed the -DI to the downside. The trend is reversing to a down trend.
STOCH LONG EXITThe %K line crosses below the %D line.
CMO SHORT ENTRY LONG CLOSEZero line crossover to downside
2025-04-17STOCH SHORT EXITThe %K line crosses above the %D line.
2025-04-23DMI LONG ENTRY SHORT CLOSEThe +DI crossed the -DI to the upside. The trend is reversing to an up trend.
CMO LONG ENTRY SHORT CLOSEZero line crossover to upside
2025-04-24WILLR LONG ENTRY SHORT CLOSE-20 crossover to upside
2025-04-28STOCH LONG EXITThe %K line crosses below the %D line.
2025-04-29STOCH SHORT EXITThe %K line crosses above the %D line.
WILLR LONG ENTRY SHORT CLOSE-20 crossover to upside
2025-05-01STOCH LONG EXITThe %K line crosses below the %D line.
CCI LONG ENTRY SHORT CLOSE100 crossover to upside
2025-05-07STOCH SHORT EXITThe %K line crosses above the %D line.
WILLR LONG ENTRY SHORT CLOSE-20 crossover to upside
2025-05-09STOCH LONG EXITThe %K line crosses below the %D line.
MFI LONG ENTRY SHORT CLOSE80 crossover to upside
2025-05-12ATR SHORT ENTRY LONG CLOSEPrice closed below (close - ATR).
MFI SHORT ENTRY LONG CLOSE80 crossover to downside
2025-05-14STOCH SHORT EXITThe %K line crosses above the %D line.
CCI LONG ENTRY SHORT CLOSE100 crossover to upside
WILLR LONG ENTRY SHORT CLOSE-20 crossover to upside
ATR LONG ENTRY SHORT CLOSEPrice closed above (close + ATR).
2025-05-16WILLR LONG ENTRY SHORT CLOSE-20 crossover to upside
MFI LONG ENTRY SHORT CLOSE80 crossover to upside
2025-05-19SAR SHORT ENTRY LONG CLOSEThe price broke the SAR to the downside
STOCH LONG EXITThe %K line crosses below the %D line.
MFI SHORT ENTRY LONG CLOSE80 crossover to downside
2025-05-21STOCH SHORT EXITThe %K line crosses above the %D line.
2025-05-22STOCH LONG EXITThe %K line crosses below the %D line.
2025-05-26SAR LONG ENTRY SHORT CLOSEThe price broke the SAR to the upside.
STOCH SHORT EXITThe %K line crosses above the %D line.
CCI LONG ENTRY SHORT CLOSE100 crossover to upside
WILLR LONG ENTRY SHORT CLOSE-20 crossover to upside
2025-05-27BB SHORT ENTRY LONG CLOSEPrice closed above the lower band.
2025-05-28STOCH LONG EXITThe %K line crosses below the %D line.
2025-05-29WILLR LONG ENTRY SHORT CLOSE-20 crossover to upside
BB SHORT ENTRY LONG CLOSEPrice closed above the lower band.
2025-05-30MFI LONG ENTRY SHORT CLOSE80 crossover to upside
2025-06-02MFI SHORT ENTRY LONG CLOSE80 crossover to downside
2025-06-04STOCH SHORT EXITThe %K line crosses above the %D line.
CCI LONG ENTRY SHORT CLOSE100 crossover to upside
2025-06-06MACD SHORT ENTRY LONG CLOSEThe MACD line crosses below the signal line.
STOCH LONG EXITThe %K line crosses below the %D line.
2025-06-10STOCH SHORT EXITThe %K line crosses above the %D line.
2025-06-11STOCH LONG EXITThe %K line crosses below the %D line.
2025-06-12SAR SHORT ENTRY LONG CLOSEThe price broke the SAR to the downside
2025-06-13DMI SHORT ENTRY LONG CLOSEThe +DI crossed the -DI to the downside. The trend is reversing to a down trend.
CMO SHORT ENTRY LONG CLOSEZero line crossover to downside
ATR SHORT ENTRY LONG CLOSEPrice closed below (close - ATR).
2025-06-16WILLR SHORT ENTRY LONG CLOSE-80 crossover to downside
2025-06-17STOCH SHORT EXITThe %K line crosses above the %D line.
CCI SHORT ENTRY LONG CLOSE-100 crossover to downside
2025-06-19STOCH LONG EXITThe %K line crosses below the %D line.
CCI SHORT ENTRY LONG CLOSE-100 crossover to downside
BB LONG ENTRY SHORT CLOSEPrice closed below the lower band.
2025-06-20STOCH SHORT EXITThe %K line crosses above the %D line.
2025-06-23BB LONG ENTRY SHORT CLOSEPrice closed below the lower band.
2025-06-26DMI LONG ENTRY SHORT CLOSEThe +DI crossed the -DI to the upside. The trend is reversing to an up trend.
SAR LONG ENTRY SHORT CLOSEThe price broke the SAR to the upside.
CMO LONG ENTRY SHORT CLOSEZero line crossover to upside
ATR LONG ENTRY SHORT CLOSEPrice closed above (close + ATR).
2025-06-27WILLR LONG ENTRY SHORT CLOSE-20 crossover to upside
ATR LONG ENTRY SHORT CLOSEPrice closed above (close + ATR).
2025-06-30MACD LONG ENTRY SHORT CLOSEThe MACD line crosses above the signal line.
STOCH LONG EXITThe %K line crosses below the %D line.
CCI LONG ENTRY SHORT CLOSE100 crossover to upside
2025-07-01WILLR LONG ENTRY SHORT CLOSE-20 crossover to upside
2025-07-03STOCH SHORT EXITThe %K line crosses above the %D line.
WILLR LONG ENTRY SHORT CLOSE-20 crossover to upside
2025-07-07STOCH LONG EXITThe %K line crosses below the %D line.
2025-07-09STOCH SHORT EXITThe %K line crosses above the %D line.
WILLR LONG ENTRY SHORT CLOSE-20 crossover to upside
2025-07-10CCI LONG ENTRY SHORT CLOSE100 crossover to upside
2025-07-11STOCH LONG EXITThe %K line crosses below the %D line.

6.3. Candlestick Patterns

Neuren Pharmaceuticals Ltd Daily Candlestick Chart
DateCandlestick Pattern

6.4. Technical Score

Let's check the technical score of Neuren Pharmaceuticals Ltd based on Penke's default Symbol scanner.

Penke's Symbol Scanner

  
  
IndicatorConditionValue
RsiGreater than5063.093
Ma 20Greater thanMa 5013.533
Ma 50Greater thanMa 10013.340
Ma 100Greater thanMa 20012.526
OpenGreater thanClose14.940
Total4/5 (80.0%)
Penke
Good job! You gained 25 XP and 0   0   10 . What's next:
  • Share my analysis of Neuren Pharmaceuticals Ltd with someone you think should read this too:
  • Are you bullish or bearish on Neuren Pharmaceuticals Ltd? Let me know what you think in the comments.
  • Do you want an email if I find something interesting about Neuren Pharmaceuticals Ltd? Add an email alert using the form below.
  • Join the community if you want to keep your earnings and track your progress: Join the community
  • Is this analysis useful to you? Support me via But Me a Coffee. I'll analyze the stock market faster for you!

Get notifications about Neuren Pharmaceuticals Ltd

I send you an email if I find something interesting about Neuren Pharmaceuticals Ltd.


Comments

How you think about this?

Leave a comment

Stay informed about Neuren Pharmaceuticals Ltd.

Receive notifications about Neuren Pharmaceuticals Ltd in your mailbox!

3rd party ad coffee SUPPORTERis ad-free.